A smartphone-delivered digital cognitive behavioral therapy (DCBT) program significantly improved symptoms of generalized anxiety disorder (GAD) in adults, according to a randomized clinical trial published in JAMA Network Open.
A smartphone-delivered digital cognitive behavioral therapy (DCBT) program significantly improved symptoms of generalized anxiety disorder (GAD) in adults, according to a randomized clinical trial published in JAMA Network Open.
In this expert Q&A, Mercedes Dodge, MPAS, PA-C, CAQ-Psychiatry, explores key topics from her session, “When Physical and Psychiatric Symptoms Collide: A Clinical Approach to Diagnosis and Treatment,” at the inaugural PA Institute.
In this expert Q&A, Mercedes Dodge, MPAS, PA-C, CAQ-Psychiatry, explores key topics from her session, “When Physical and Psychiatric Symptoms Collide: A Clinical Approach to Diagnosis and Treatment,” at the inaugural PA Institute.
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
